Edwards announced that the U.S. District Court for the District of Columbia granted the motion from the U.S. Federal Trade Commission (FTC) for an injunction to block the company’s proposed acquisition of JenaValve. As a result, the company will not acquire JenaValve.

The FTC sued to block the deal in August, saying the transaction would limit access to lifesaving devices to treat a potentially fatal heart condition. Edwards announced its intent to acquire JenaValve in July 2024—the company had hoped to add JenaValve’s Trilogy heart valve system for severe aortic regurgitation (AR) to its transcatheter aortic valve replacement (TAVR) portfolio.

“This is a major win for the Trump-Vance administration,” FTC spokesperson Joe Simonson told Reuters. “We will never stop working to promote innovation, lowering healthcare costs, and saving American lives.”

Edwards commented in a press release that it disagreed with the decision and “believes that the acquisition would have been in the best interest of a large, growing and underserved group of patients.”

The deal for JenaValve was revealed amid a number of deals during that time. Edwards also revealed it would purchase Innovalve, as well as Endotronix and JC Medical. The company also struck mitral valve deals with Affluent Medical.

Edwards said it would continue to provide novel therapies and evidence to transform patient care, including advancing the SOJOURN transcatheter AR valve and enrolling patients in the JOURNEY pivotal trial.

As a result of this update, the company revised its full-year 2026 adjusted earnings per share (EPS) guidance to $2.90-$3.05 from its earlier guidance of $2.80-$2.95.